Press releasePRNewswire
Anixa Biosciences
ANIX · NASDAQ
$2.68+$0.07 (+2.68%)TodayMarket closed ·
Prev close $2.61
Latest news
- Press releasePRNewswire
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
- Press releasePRNewswire
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
- Press releasePRNewswire
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
- Press releasePRNewswire
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
- Press releasePRNewswire
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
- Press releasePRNewswire
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
- Press releasePRNewswire
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
- Press releasePRNewswire
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Press releasePRNewswire
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
- Press releasePRNewswire
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
- Press releasePRNewswire
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
- Press releasePRNewswire
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
- Press releasePRNewswire
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
- Press releasePRNewswire
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
- Press releasePRNewswire
/C O R R E C T I O N -- Anixa Biosciences, Inc./
- Press releasePRNewswire
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
- Press releasePRNewswire
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
- Press releasePRNewswire
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
- Press releasePRNewswire
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
- Press releasePRNewswire
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
- Press releasePRNewswire
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
- Press releasePRNewswire
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
- Press releasePRNewswire
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
- News
Anixa Biosciences Receives South Korean Patent Allowance For Breast Cancer Vaccine Technology Licensed From Cleveland Clinic
- Press releasePRNewswire
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
- Press releasePRNewswire
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
- News
Anixa Biosciences Issues Update On Patient Outcomes Observed In Ongoing Phase 1 Ovarian Cancer CAR-T Clinical Trial, Following Regulatory Approval Of Protocol Amendment That Enables Substantial Dose Escalation
- Press releasePRNewswire
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
- NewsVandana Singh
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.